Graham Holdings Company (GHC)

Executive Summary / Key Takeaways

• Graham Holdings' diversification into education and healthcare is generating strong operating leverage that is being partially offset by the secular decline of its legacy media assets, creating a potential sum-of-the-parts disconnect at current valuations.
• The education segment, representing 35% of revenue, delivered 23.6% operating income growth on just 3% revenue growth in 2025, demonstrating pricing power and cost discipline despite regulatory headwinds in international markets.
• Healthcare has emerged as a genuine growth engine with 33% revenue growth and 86% operating income expansion, yet the segment still represents less than 17% of total revenue, suggesting substantial runway for value creation if management continues allocating capital here.
• The television broadcasting division's 21% revenue decline and 43% operating income collapse is a known headwind with finite duration, but management's commentary on continued retransmission pressure suggests this drag will persist through 2026.
• Trading at 0.96x book value and 9.63x EV/EBITDA with a net cash position, the market appears to price GHC as a melting ice cube rather than a diversified holding company with two growing segments helping to mitigate the impact of one declining one.

Setting the Scene: The Washington Post's Second Act

Graham Holdings Company, founded in 1877 as The Washington Post Company and headquartered in Arlington, Virginia, has spent the past decade executing one of the most deliberate corporate transformations in modern media history. The 2013 rebranding from a newspaper publisher to a diversified holding company was not merely cosmetic—it represented a fundamental acknowledgment that the economics of traditional media had permanently changed. Today, GHC operates as a collection of five distinct divisions spanning educational services, television broadcasting, healthcare, manufacturing, and automotive dealerships, with a grab bag of "Other Businesses" ranging from restaurants to custom framing to podcast monetization platforms.

This structure matters because it defies easy categorization. The company cannot be valued as a pure-play education stock like Grand Canyon Education (LOPE) or Adtalem Global Education (ATGE), nor as a healthcare services company, nor as a manufacturer. Instead, it must be understood as a capital allocation vehicle managed by the Graham family, who have demonstrated a willingness to exit declining businesses (the Post itself, sold to Jeff Bezos in 2013) and redeploy capital into growing sectors. The significance lies in whether this diversification creates value through stability or destroys it through complexity and conglomerate discount.

The company's place in the value chain varies dramatically by segment. In education, Kaplan operates as both a direct-to-consumer test preparation provider and a B2B services partner to universities like Purdue Global, capturing value through managed services fees and revenue-sharing agreements. In healthcare, CSI Pharmacy functions as a specialty home infusion provider, sitting between drug manufacturers and patients, while Graham Healthcare Group provides home health and hospice services directly to Medicare and private payors. Manufacturing businesses like Hoover and Dekko are tier-2 suppliers to commercial construction and industrial OEMs, while the automotive dealerships are classic retail intermediaries between manufacturers and consumers. This fragmentation means GHC lacks the concentrated bargaining power of a pure-play competitor but gains resilience from multiple economic exposures.

History with Purpose: From Ink to Infusions

The 2013 name change to Graham Holdings Company marked the beginning of a systematic pivot away from media dependence. Between 2014 and 2018, the company installed new leadership—Andrew Rosen as Executive Vice President in 2014 and Timothy O'Shaughnessy as CEO in 2015—signaling a generational shift in strategy. The pivotal 2018 Transition and Operations Support Agreement (TOSA) with Purdue Global, which included a $20 million advance, demonstrated that Kaplan's future lay not in operating its own universities but in providing infrastructure to institutions navigating the digital transition. This strategic repositioning from owner to enabler would define the education segment's subsequent evolution.

The 2019-2023 period reveals a pattern of opportunistic capital deployment into healthcare while managing decline elsewhere. The 2019 acquisition of Clarus for patient call management solutions and the 2021-2022 purchases of Impact Medical, Skin Clique, and Surpass show a deliberate buildout of a healthcare ecosystem. These moves coincided with the 2021 borrower defense to repayment (BDTR) applications seeking $35 million in loan discharges—a regulatory overhang that continues to cast a shadow over Kaplan's legacy operations. The 2023 goodwill impairments at Dekko and WGB, driven by "sustained demand weakness," provided honest acknowledgment that not all acquisitions create value, a refreshing contrast to promotional management teams that refuse to recognize mistakes.

The 2024-2025 acceleration in deal activity suggests management sees opportunity in market dislocations. The $653.4 million pension settlement gain in late 2024 provided both balance sheet flexibility and a reminder that legacy liabilities can become assets when managed creatively. The November 2025 debt restructuring—issuing $500 million in new notes to redeem existing debt—reduced refinancing risk while the $205 million settlement of mandatorily redeemable noncontrolling interests simplified the capital structure. These financial engineering moves demonstrate a focus on cost of capital at a time when many conglomerates simply allow their balance sheets to atrophy.

Segment Dynamics: Where Value Is Created and Destroyed

Education: The Steady Compounders

The education division's 2025 performance tells a story of mature businesses managed for cash flow rather than growth. The 3% revenue increase to $1.74 billion masks significant divergence between subsegments. Kaplan International's flat revenue (-2% constant currency) reflects the harsh reality of international student recruitment in an era of visa restrictions. Management's commentary that "U.S. visa policies and practices materially adversely affected recruitment" represents a direct hit to the US Pathways business, which relies on bringing international students to American campuses. The UK government's elimination of VAT exemptions for private schools, effective January 2025, triggered a $22.9 million impairment at MPW and materially impacted enrollment, demonstrating how regulatory changes can instantly alter the economics of acquired businesses.

Yet the 23.6% operating income growth to $166 million reveals the power of operational leverage. Kaplan Higher Education's 8% revenue growth and 38.4% operating income expansion, driven by a 4% enrollment increase at Purdue Global and a fee rate increase from 12.5% to 13%, shows the scalability of the managed services model. The TOSA structure—where Kaplan receives 13% of Purdue Global's revenue plus an 8% service fee—creates a high-margin, capital-light annuity that grows with the partner's success. This is fundamentally different from the for-profit college model that attracted regulatory scrutiny; Kaplan now bears no student loan risk while capturing upside from institutional growth.

Supplemental Education's 9% revenue and 24% operating income growth demonstrates the enduring demand for high-stakes test preparation. In a world where professional licensure remains mandatory and graduate school admissions still value standardized tests, Kaplan's brand and content libraries provide defensible moats. The competition from lower-cost and free test preparation products is real, but the company's ability to grow both revenue and margins suggests that quality and outcomes still command premium pricing in credential-driven markets.

Healthcare: The Emerging Star

The healthcare division's 33% revenue growth and 86% operating income expansion to $97.4 million represents the most compelling story in the entire company. CSI Pharmacy's 55% revenue growth to $465.5 million, driven by expansion of infusion treatment offerings and patient service areas, positions it to capture the massive shift from hospital-based to home-based specialty drug administration. The specialty home infusion market is highly competitive, but CSI's nationwide license in all 50 states and focus on immunoglobulin therapy create a differentiated platform that can serve rare disease patients overlooked by larger, more generalized competitors.

The "Other Healthcare" segment's 234% operating income growth to $44 million, on just 12% revenue growth, reveals dramatic operational improvements across home health, hospice, and physician services. The reduction in pension expense contributed, but the underlying businesses are clearly scaling. The home health and hospice industries are extremely competitive and fragmented, but Graham Healthcare Group's ability to differentiate on response time, clinical programming, clinical outcomes and patient satisfaction suggests a focus on quality over price competition that can sustain margins even as Medicare payment pressures intensify.

The 2026 Home Health Rule's 1.3% payment reduction is a headwind, but the segment's 2025 performance demonstrates sufficient operating leverage to absorb such cuts. The real risk lies in the severe shortage of nurses, which could limit growth and increase labor costs. However, the 33% revenue growth suggests GHC is managing this constraint better than competitors, potentially through better technology or more efficient care models.

Television Broadcasting: The Melting Ice Cube

Graham Media Group's 21% revenue decline and 43% operating income drop to $117.7 million represents the thesis's primary risk. The segment generated $206.6 million in operating income in 2024, meaning the $90 million decline erased nearly half the division's earnings power. Management's commentary is clear: retransmission revenues, net of network fee expense, declined in 2025 with this trend expected to continue in the future due largely to adverse subscriber trends from cord cutting. This is not a structural erosion of the business model.

The operating margin compression from 38% to 26% shows that fixed costs remain while revenues decline. Television stations have high fixed costs—tower leases, FCC licenses, newsroom staff—that cannot be easily reduced as advertising and retransmission revenues shrink. The transition to ATSC 3.0 across all stations is necessary for technical relevance but requires capital investment without clear revenue upside. The increasing availability of network programming on direct-to-consumer platforms could decrease local broadcasters' leverage in retransmission consent negotiations, creating a negative feedback loop where content owners bypass local stations entirely.

The political advertising cycle provided a temporary boost in 2024, but the 2025 decline reveals the underlying trend. For investors, the key question is whether this segment's decline is linear or accelerates. If management can stabilize revenues at current levels and maintain 26% margins, the segment still generates substantial cash flow that can be redeployed into growing divisions.

Manufacturing and Automotive: The Cyclical Ballast

The manufacturing segment's 10% revenue growth and 8.5% operating income increase to $31.7 million demonstrates the mixed impact of acquisitions. The Arconic (ARNC) acquisition drove Hoover's revenue growth but also brought significant transaction, transition and intangible asset amortization costs and coincided with a substantial decline in Hoover's core fire-retardant wood product business from the continued sluggish multi-family housing market. This illustrates the challenge of buying growth in cyclical industries—acquisitions can mask underlying demand weakness.

Dekko's improvement in commercial office power and data products, along with medical equipment assembly, shows that niche manufacturing can generate stable returns when focused on specialized applications. JoyceDayton and Forney's modest contributions demonstrate the portfolio's diversification within manufacturing itself, reducing dependence on any single end market.

The automotive segment's 6% revenue decline and 26% operating income drop to $28.1 million reflects industry-wide inventory normalization after the supply-constrained years of 2021-2023. The closure of the Ourisman Jeep of Bethesda dealership and $10.1 million impairment charge on the CDJR franchise shows management's willingness to exit underperforming assets. The Honda (HMC) of Woodbridge acquisition in October 2025 suggests a focus on brands with better long-term prospects, but the segment remains exposed to cyclical downturns and the long-term threat of EV transition disrupting dealership economics.

Financial Performance: The Conglomerate Math

Consolidated revenue growth of 3% to $4.91 billion in 2025 masks a tale of two companies. The education and healthcare divisions grew operating income by $76.8 million combined, while television broadcasting declined by $88.9 million. This dynamic explains why consolidated operating income excluding impairments was essentially flat year-over-year. The $653.4 million pension settlement gain in 2024 created an optical earnings decline in 2025, but the underlying operating performance shows stability.

Cash flow generation remains robust. Operating cash flow of $339.5 million and free cash flow of $267.7 million represent conversion rates of 115% and 91% of net income, respectively, even after adjusting for the non-cash pension gain. The company's net cash position of approximately $519.6 million provides strategic flexibility. The $191 million of cash held outside the US, with $6 million not immediately available, is a minor constraint but manageable given domestic liquidity.

The balance sheet's debt-to-equity ratio of 0.30 is conservative compared to peers. The November 2025 debt restructuring, which issued $500 million in new notes to redeem existing debt and refinance credit facilities, likely lowered interest costs and extended maturities. This financial engineering reduces the cost of capital for future acquisitions, particularly in healthcare where valuations remain elevated.

Competitive Positioning: The Diversification Discount

GHC's valuation multiples reveal a stark discount to focused education peers. ATGE trades at 9.92x EV/EBITDA with 22.88% operating margins and 18.03% ROE, while LOPE commands 13.01x EV/EBITDA with 35.08% operating margins and 28.24% ROE. GHC's 9.63x EV/EBITDA, 6.55% operating margin, and 6.48% ROE appear inferior until one considers the conglomerate structure. The television broadcasting segment's 26% operating margin is respectable for media but dilutes the consolidated figure. Similarly, the automotive segment's thin margins reflect retail economics rather than any operational deficiency.

The key insight is that GHC's diversification creates a conglomerate discount that may be unwarranted. ATGE's focused strategy on healthcare education generates higher margins but exposes the company to regulatory risk and single-sector downturns. LOPE's dependence on Grand Canyon University creates concentration risk that GHC's multi-institution model avoids. Stride (LRN), with its K-12 focus, limits its addressable market compared to Kaplan's global professional education footprint. Pearson (PSO) has impressive global scale, but its 12.05x EV/EBITDA and slower growth reflect maturity.

The moat lies in its ability to allocate capital across sectors. While pure-play competitors must accept their industry's cyclicality, GHC can harvest cash from declining segments and redeploy into growing ones. This flexibility is undervalued by markets that prefer pure-play narratives. The risk is that management allocates capital poorly, as the Dekko and WGB impairments suggest occurred in recent years.

Risks: The Thesis Breakers

The most material risk is regulatory capture in education. The March 20, 2025 executive order directing the Department of Education's dismantling creates unprecedented uncertainty. As a third-party servicer to Purdue Global, Kaplan North America is jointly and severally liable for Title IV violations, meaning changes in ED regulations could impose massive compliance costs or revenue-sharing restrictions. The potential revision of incentive compensation rules could force renegotiation of the Purdue Global agreement, which currently provides 13% of revenue plus an 8% service fee. Any reduction in this rate would directly impact Kaplan Higher Education's $56.4 million operating income.

The BDTR claims, while defended vigorously, represent a contingent liability that could reach beyond the initial $35 million. The Sweet v. Cardona settlement's inclusion of former Kaplan University and Purdue Global students suggests the Department of Education may pursue broader claims against for-profit education servicers. A material adverse judgment could require both financial settlement and operational changes that impair the TOSA model's profitability.

International education regulatory tightening poses a multi-front threat. Australia's 80% visa approval allocation threshold, the UK's VAT exemption elimination, and US visa office closures collectively create a "perfect storm" for Kaplan International's US Pathways and UK Professional businesses. The 2% constant currency revenue decline in 2025 could accelerate if these policies intensify, potentially offsetting gains in Singapore and other markets.

Television broadcasting's secular decline could accelerate beyond management's expectations. If cord-cutting shifts from linear to exponential, retransmission revenues might fall faster than the 21% decline seen in 2025. The ATSC 3.0 transition requires capital investment without clear ROI, and network reverse retransmission fee escalations could compress margins further. A major network deciding to bypass local affiliates entirely would eliminate the segment's primary revenue stream.

Outlook and Execution: The Capital Allocation Test

Management's 2026 guidance provides limited visibility but hints at strategic priorities. Capital expenditures of $90-100 million suggest continued investment in growth segments, likely healthcare facility expansion and manufacturing automation. The $97 million net pension credit will boost reported earnings but represents non-cash income that should be excluded from operational analysis. The $7.52 per share dividend signals capital return discipline but also suggests limited high-ROI reinvestment opportunities.

The healthcare division's trajectory is critical. With 33% revenue growth and strong margins, it could become the largest operating division within three to five years if current trends persist. The August 2025 acquisition of Pine Drug Holdings and California pharmacy license acquisition position CSI for West Coast expansion, potentially adding $100+ million in annual revenue. However, the 1.3% Medicare payment cut in 2026 and nursing shortage constraints could limit margin expansion.

In education, management's commentary suggests UK Professional and Singapore will offset US Pathways weakness, but the 2% constant currency decline indicates this is not yet happening. The Ohana Institute acquisition in June 2025, a K-12 private school in Florida, represents a small bet on project-based learning models but is immaterial to segment results.

The television broadcasting outlook remains grim. Management explicitly states retransmission revenue decline is expected to continue in the future, and the absence of 2026 political advertising means another down year is likely. The key question is whether the segment can maintain its $117.7 million operating income level or if further declines are coming.

Valuation Context: The Sum-of-Parts Opportunity

At $1,050.56 per share, GHC trades at a market capitalization of $4.58 billion and enterprise value of $4.70 billion. The 0.96x price-to-book ratio suggests the market values the company below its accounting equity, a rare occurrence for a profitable, cash-generating business. The 9.63x EV/EBITDA multiple compares favorably to the 9.92x for ATGE and 13.01x for LOPE, despite similar or better growth prospects in the healthcare segment.

The 15.8x P/E ratio appears reasonable but masks the earnings quality issue. The 2024 pension gain inflated the prior year baseline, making the 2025 decline appear worse than the underlying operational reality. Adjusting for the $653 million non-cash gain, normalized earnings power appears closer to $400-450 million, implying a P/E of 10-11x on a clean basis. The 6.55% operating margin is depressed by media losses; education and healthcare combined likely operate at 12-15% margins, comparable to pure-play peers.

Free cash flow yield of 5.8% provides downside protection. The 0.72% dividend yield with a 10.83% payout ratio suggests ample capacity for dividend growth or share repurchases. The 0.81 beta indicates lower volatility than the market, consistent with conglomerate structure.

Relative to peers, GHC's diversification provides a measure of stability. ATGE's 53% debt-to-equity ratio creates financial risk that GHC's 30% ratio avoids. LOPE's 4.21x price-to-sales multiple reflects growth expectations that GHC's 0.93x multiple does not incorporate. LRN's 5.38% operating margin is lower than GHC's consolidated figure despite being a pure-play education company. PSO's 18.51x P/E and 2.71% dividend yield suggest mature growth, while GHC offers similar yield with better growth prospects in healthcare.

Conclusion: The Conglomerate's Hidden Optionality

Graham Holdings' investment thesis hinges on whether management can accelerate capital allocation into healthcare while managing the media segment's decline. The 2025 results provide evidence of this strategy in action: education and healthcare generated $76.8 million in additional operating income, which helped to offset broadcasting's $88.9 million decline. As healthcare grows from 17% to 25-30% of revenue over the next three years, its contribution will overwhelm media's drag, revealing the underlying earnings power of the enterprise.

The regulatory risks in education are real but manageable. The Purdue Global TOSA provides a stable, growing revenue stream that is insulated from student loan discharge risk, while Kaplan International's diversification across Singapore, UK, and other markets reduces dependence on any single regulatory regime. The BDTR overhang, while concerning, appears limited to legacy operations and is being vigorously defended.

The primary catalyst for value realization is either a spin-off of the media assets or continued healthcare acquisitions that shift the portfolio mix. Management's 2025 acquisition pace—two healthcare businesses, Arconic in manufacturing, and a Honda dealership—suggests they are actively reallocating capital. The $177.5 million available on the credit facility and strong cash generation provide dry powder for larger deals.

Trading below book value with a 5.8% free cash flow yield, GHC offers downside protection while providing optionality on management's capital allocation skill. If healthcare maintains 20-30% growth and media stabilizes, the company could generate $500 million in operating income by 2027, supporting a stock price 30-40% higher. The key variables to monitor are healthcare segment margins, Purdue Global enrollment trends, and any acceleration in media revenue decline. For patient investors, the diversification discount appears overdone, offering an attractive risk/reward in a market obsessed with pure-play narratives.